|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
|D018352||Coronavirus Infections NIH||0.03|
There is one clinical trial.
The Harnessing Online Peer Education COVID-19 (HOPE COVID-19) intervention will assess whether a peer-led online support community can improve behavioral health outcomes related to COVID-19.
Description: GAD-7. Items reference feelings of anxiousness, worry, fear, and irritability and are rated on a frequency scale from 0 ("not at all") to 3 ("nearly every day"). Sum scores are typically reported (range: 0-21), with scores of 0-4, 5 to 9, 10 to 14, and 15 to 21 having been proposed to differentiate between minimal, mild, moderate, and severe symptom experiencesMeasure: Anxiety Time: 6 week
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports